Skip to content
Gene2Rx home

Try

Loading…

Search couldn't load. Check your connection and try again, or use the medication lookup.

No pages match .

The medication lookup checks any medication by name, including ones without their own page.

Get my report
In the Full Report

Nateglinide

Antidiabetics (Meglitinide)

Nateglinide (Starlix, and generic tablets) is a short-acting tablet taken before meals to lower blood sugar in adults with type 2 diabetes. CYP2C9 carries out about 70% of its metabolism [1]. People with two copies of the reduced-function CYP2C9*3 allele cleared it about half as fast in a study of healthy volunteers, though the effect on blood sugar was small [2]. The FDA lists CYP2C9 poor metabolizers as a group in whom a lower dose and more frequent glucose checks are recommended because of the risk of low blood sugar [3].

At a glance
Brand namesStarlix; generic nateglinide tablets
Used forWith diet and exercise, improving blood sugar control in adults with type 2 diabetes (not for type 1 diabetes or diabetic ketoacidosis)
GenesCYP2C9
GuidanceFDA Table of Pharmacogenetic Associations; FDA label (Section 7); no CPIC guideline

How nateglinide works

Nateglinide is a glinide (also called a meglitinide). It closes ATP-sensitive potassium channels on the insulin-making beta cells of the pancreas, which triggers insulin release. The effect depends on glucose: less insulin is released when blood sugar is low. Insulin rises within 20 minutes of a dose, peaks about an hour later and is back to baseline by 4 hours, which is why it is taken 1 to 30 minutes before each meal [1].

The usual dose is 120 mg three times a day before meals, or 60 mg three times a day for people already near their glucose goal [1]. Its main risk is hypoglycemia (low blood sugar). The label warns that severe hypoglycemia can cause seizures and can be life-threatening, and that symptoms may be harder to notice in people with long-standing diabetes, nerve damage or on beta-blockers [1].

Laboratory studies show nateglinide is metabolized mainly by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). The main metabolites are weaker than the parent drug, and the half-life is about 1.5 hours [1]. With such a short half-life, slower clearance mainly raises and prolongs the level after each dose rather than building up from day to day.

How CYP2C9 affects nateglinide

CYP2C9 variants are named as star alleles. The two common reduced-function alleles are *2 (decreased function) and *3 (no function). Each person has two copies, and the Clinical Pharmacogenetics Implementation Consortium (CPIC) adds up their activity values to assign a group: normal (score 2), intermediate (1.5 or 1) or poor (0.5 or 0) metabolizer. *2/*3 and *3/*3 are poor metabolizer genotypes [4].

The clearest human data come from a 2004 study that gave a single 180 mg dose to 26 healthy volunteers selected by genotype, with a glucose drink at intervals [2]:

Median nateglinide clearance by CYP2C9 genotype
GenotypeMedian total clearance (L/h)
*1/*17.9
*1/*28.4
*2/*26.5
*1/*36.9
*2/*35.8
*3/*34.1

Clearance was significantly lower in carriers of *3, while *2 carriers were similar to *1/*1. Despite this, blood glucose, insulin and glucagon did not differ significantly between genotypes. A model built from the data found only a minor genetic effect on insulin and glucose, and predicted that people with *3/*3 might have a slightly higher risk of hypoglycemia, particularly at doses above 120 mg. The authors concluded the effect may become relevant in people with diabetes [2]. The study was small, used single doses in people without diabetes, and had few people in each genotype group.

What the guidelines recommend

The FDA's Table of Pharmacogenetic Associations lists nateglinide in Section 1 for CYP2C9 poor metabolizers: higher systemic concentrations, a possible higher risk of hypoglycemia, a recommended dose reduction and more frequent monitoring for adverse reactions, with a pointer to the label for specific doses [3]. The generic label's drug interaction table places "patients known to be poor metabolizers of CYP2C9 substrates" alongside CYP2C9 inhibitors among factors that may increase the glucose-lowering effect, and says dose reductions and more frequent glucose monitoring may be required. It gives no specific reduced dose [1]. CPIC has not assigned a level to nateglinide or published a guideline [5].

CYP2C9 results and nateglinide (FDA)
ResultWhat it meansGuideline recommendation
Normal Metabolizer Usual clearance. No FDA guidance for this result. Usual starting dose.
Intermediate Metabolizer No FDA guidance for this result. Usual starting dose.
Poor Metabolizer Higher systemic concentrations; may raise the risk of hypoglycemia. A dose reduction is recommended, with more frequent monitoring for adverse reactions, including low blood sugar. The label gives no specific dose.
Indeterminate or not available The alleles found could not be assigned a function, or the gene could not be called. No genotype-based advice; usual starting dose.

In the 2004 study, *1/*3 (an intermediate genotype) also had somewhat lower clearance than *1/*1 [2], but the FDA makes no recommendation for intermediate metabolizers.

Want to know what your genetics say about how you'll respond to Nateglinide?

A Gene2Rx report reads your own DNA to show how it may affect your response to Nateglinide and your other medications.

Using your result

If your report shows a CYP2C9 poor metabolizer result and nateglinide is being considered or is already prescribed, share it with your prescriber. The practical steps are the ones the FDA describes: a lower dose and more frequent glucose checks, and knowing the signs of low blood sugar. Do not start, stop or change a medicine on the strength of a genetic result without your prescriber.

Other medicines matter as much as genotype. The label names amiodarone, fluconazole, voriconazole and sulfinpyrazone as CYP2C9 inhibitors that may increase nateglinide's glucose-lowering effect, along with NSAIDs, salicylates, non-selective beta-blockers, MAO inhibitors and alcohol. Inducers such as rifampin, phenytoin and St John's wort may weaken it [1]. The label also lists changes in meals or physical activity, other diabetes medicines, and kidney or liver impairment among factors that raise hypoglycemia risk generally [1].

What this result cannot tell you

Gene2Rx reads the variant calls in the file you upload. Consumer arrays from 23andMe, AncestryDNA and MyHeritage are not clinical-grade tests, and their raw data is labeled not for medical use. Arrays read fixed positions, and processing uses imputation to infer some variants that were not measured. A normal result means none of the assessed CYP2C9 variants was found among the positions your data covers or imputation inferred; it cannot rule out a rare variant elsewhere.

The evidence linking CYP2C9 to nateglinide's effect is limited to one small single-dose study in healthy volunteers, which found a clear change in drug clearance but no significant change in glucose [2]. How much a genotype changes hypoglycemia risk in people with diabetes taking the drug every day has not been measured. Meals, activity, other diabetes medicines and kidney or liver function also affect the risk [1]. If a clinical laboratory has already reported your CYP2C9 genotype, those results can be entered for a Panel Report.

Common questions

I'm a CYP2C9 poor metabolizer. Can I take nateglinide?

Yes, the FDA does not advise against it. It recommends a lower dose and closer monitoring for low blood sugar.

Does the intermediate metabolizer result change anything?

The FDA gives no advice for intermediate metabolizers, and the usual starting dose applies.

Sources and further reading

  1. Nateglinide tablets, prescribing information. Dr. Reddy's Laboratories. DailyMed. Indication, dosing, hypoglycemia warning (5.1), drug interactions including CYP2C9 poor metabolizers (7), pharmacokinetics (12.3).
  2. Kirchheiner J et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet (2004). Clearance by CYP2C9 genotype in 26 volunteers.
  3. FDA. Table of Pharmacogenetic Associations. Nateglinide with CYP2C9 poor metabolizers in Section 1.
  4. Karnes JH et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther (2021). CYP2C9 allele functions and the activity score system.
  5. CPIC. Gene-drug pairs and CPIC levels (spreadsheet). Nateglinide does not appear in CPIC's list of gene-drug pairs.
Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested